SCHEMBL386368

SCHEMBL386368

CCOP(OCC)N(C(C)C)C(C)C

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15314806 0.90
SCHEMBL13012147 0.89
SCHEMBL24201802 0.82
SCHEMBL13671281 0.82
SCHEMBL566248 0.80 TSHR (0.31)
SCHEMBL12767708 0.79 HSD17B10 (0.31)
SCHEMBL7572703 0.78 LMNA (0.30) LMNA
SCHEMBL13136018 0.78 LMNA (0.30) LMNA
SCHEMBL25408699 0.77
SCHEMBL20019832 0.76 ALDH1A1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115772192-A Preparation method of fosfomycin trometamol EP impurity C 深圳鼎邦化学品有限公司 2023-03-10 CN claimed
EP-2069339-B1 SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES WOCKHARDT RESEARCH CENTER (IN) 2011-05-18 EP claimed
US-20100120721-A1 SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES WOCKHARDT RESEARCH CENTRE (IN) 2010-05-13 US claimed
EP-2069339-A2 SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES Wockhardt Research Centre (IN) 2009-06-17 EP claimed
WO-2008038092-A2 SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES WOCKHARDT RESEARCH CENTRE (IN) 2008-04-03 WO claimed
CN-119490394-A Isobutene hydroformylation catalytic system and method for catalytic synthesis of isovaleraldehyde 宁夏天新药业有限公司 2025-02-21 CN disclosed
CN-115772192-A Preparation method of fosfomycin trometamol EP impurity C 深圳鼎邦化学品有限公司 2023-03-10 CN disclosed
US-20200033361-A1 Detection and Quantitation Method for Proteomics of Post-Translational Modifications SICHUAN UNIVERSITY (CN) 2020-01-30 US disclosed
CN-108627647-A A kind of detection of posttranslational modification proteomics and quantitative approach 四川大学 2018-10-09 CN disclosed
CN-101821277-B Tetrahydropyran nucleic acid analogs ISIS PHARMACEUTICALS INC 2014-05-07 CN disclosed
EP-2647644-A1 2'-O-MODIFIED RNA Chiralgen, Ltd. (JP) 2013-10-09 EP disclosed
CN-103180463-A A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide ROCHE DIAGNOSTICS GMBH 2013-06-26 CN disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed
US-20030144499-A1 Photocleavable protecting groups and methods for their use AFFYMETRIX, INC. (US) 2003-07-31 US disclosed
US-6566515-B1 Performing photochemical reactions on a surface; prepare chemical mixture, apply to surface, irradiate, monitor generation of reaction product AFFYMETRIX, INC. 2003-05-20 US disclosed
US-6147205-A ARYLALKYLOXYCARBONYL GROUPS; FOR SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND POLYPEPTIDES AFFYMETRIX, INC. (US) 2000-11-14 US disclosed
WO-1998039348-A9 PHOTOCLEAVABLE PROTECTING GROUPS AND METHODS FOR THEIR USE 1999-02-18 WO disclosed
WO-1998039348-A1 PHOTOCLEAVABLE PROTECTING GROUPS AND METHODS FOR THEIR USE AFFYMETRIX, INC. (US) 1998-09-11 WO disclosed
US-4228109-A HERBICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT LMNA 4143/4885
US-20100120721-A1 SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES CYP2C19, ALPI, CYP3A7 LMNA 4092/4885
US-20030144499-A1 Photocleavable protecting groups and methods for their use RTCB, RRS1, GAR1 LMNA 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.